Foghorn Therapeutics (FHTX) CFO files Form 3 insider ownership

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. filed a Form 3 for Chief Financial Officer Maynard Ryan D, providing his initial statement of beneficial ownership in the company’s stock. The filing does not list any specific share transactions, focusing instead on establishing his reporting status as an executive officer.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Maynard Ryan D

(Last) (First) (Middle)

99 COOLIDGE AVENUE

SUITE 500

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/23/2026

3. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

	/s/ Michael LaCascia, Attorney-in-Fact for Ryan D. Maynard	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Foghorn Therapeutics (FHTX) Form 3 filing report?

The Form 3 filing reports Chief Financial Officer Maynard Ryan D as an insider with beneficial ownership in Foghorn Therapeutics Inc.. It serves as his initial ownership statement and does not include any specific share transaction details or trade activity.

Who is the reporting person in Foghorn Therapeutics (FHTX) latest Form 3?

The reporting person is Maynard Ryan D, who serves as Chief Financial Officer of Foghorn Therapeutics Inc. The filing identifies him as an officer subject to insider reporting requirements and records his initial beneficial ownership position without describing individual trades.

Does the Foghorn Therapeutics (FHTX) Form 3 show any stock trades?

No, the Form 3 for Foghorn Therapeutics Inc. does not show any stock trades. The transactions section is empty, indicating no reported purchases, sales, acquisitions, or dispositions, and the focus is solely on establishing the CFO’s initial beneficial ownership status.

What insider role triggers reporting in the Foghorn Therapeutics (FHTX) Form 3?

The reporting obligation arises because Maynard Ryan D is an officer, specifically the Chief Financial Officer of Foghorn Therapeutics Inc. As a senior executive, he must file a Form 3 to disclose his initial beneficial ownership in the company’s securities.

Does the Foghorn Therapeutics (FHTX) Form 3 mention any large ownership stake?

The Form 3 indicates that Maynard Ryan D is not listed as a ten percent owner of Foghorn Therapeutics Inc. It classifies him solely as an officer, the Chief Financial Officer, without identifying him as holding at least ten percent of the company’s shares.